Information from the subgroup analyses of the section 3 DESTINY-Breast05 trial demonstrated that post-neoadjuvant administration of Enhertu (T-DXd; fam-trastuzumab deruxtecan-nxki) led to...
The U.S. Meals and Drug Administration has granted breakthrough remedy designation to Enhertu (fam-trastuzumab deruxtecan-nxki) for grownup sufferers with HER2-positive early breast...
